Loading…
Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging
Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retai...
Saved in:
Published in: | The Journal of biological chemistry 2018-06, Vol.293 (23), p.9030-9040 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453 |
---|---|
cites | cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453 |
container_end_page | 9040 |
container_issue | 23 |
container_start_page | 9030 |
container_title | The Journal of biological chemistry |
container_volume | 293 |
creator | Long, Nicholas E. Sullivan, Brandon J. Ding, Haiming Doll, Stephanie Ryan, Michael A. Hitchcock, Charles L. Martin, Edward W. Kumar, Krishan Tweedle, Michael F. Magliery, Thomas J. |
description | Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent. |
doi_str_mv | 10.1074/jbc.RA118.002538 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5995523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820372148</els_id><sourcerecordid>29669811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi1ERZfCnRPyAzRb20nWMQekVQUFaSWkqpV6sxx7kkxJ7MjOVloegaeu6UIFB3wZj2f-fzz6CHnH2ZozWV3ct3Z9veW8WTMm6rJ5QVacNWVR1vzuJVnlR14oUTen5HVK9yyfSvFX5FSozUY1nK_Izx367xAp-B49QETfU_TU-AWLm-1VIcXTvQ3uQLto-gn8kmiYF5zwByTaYpiHQ0JrRjrHMENcENI5TRD3Ex3M2BUjdnCeXRwdsB-KNIPFDi0uB7rspxApTiYP79-Qk86MCd7-jmfk9vOnm8svxe7b1dfL7a6wVSWXQtlNC46pRhilpKwsc9KZjZCdrFqlKlmL2glRV23TNIq5KmeKtUYaZV3OyjPy8eg779sJnM0bRTPqOeZ_xIMOBvW_FY-D7sODrpWqa1FmA3Y0sDGkFKF71nKmf3HRmYt-4qKPXLLk_d8znwV_QOSGD8cGyJs_IESdLIK34DCCXbQL-H_3R0C6oO0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><source>PubMed (Medline)</source><source>ScienceDirect®</source><creator>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</creator><creatorcontrib>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</creatorcontrib><description>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.RA118.002538</identifier><identifier>PMID: 29669811</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antibody Affinity ; antibody engineering ; Antigens, Neoplasm - analysis ; Antigens, Neoplasm - immunology ; Cell Line, Tumor ; Cloning, Molecular ; colorectal cancer ; drug development ; Female ; Glycoproteins - analysis ; Glycoproteins - immunology ; Humans ; immunohistochemistry ; in vivo imaging ; Mice ; Mice, Inbred BALB C ; mucin ; Neoplasms - diagnostic imaging ; oligomerization ; Positron-Emission Tomography ; Protein Engineering ; protein stability ; Protein Structure and Folding ; Single-Chain Antibodies - blood ; Single-Chain Antibodies - genetics ; Single-Chain Antibodies - immunology ; Single-Chain Antibodies - pharmacokinetics ; Tissue Distribution ; tumor marker</subject><ispartof>The Journal of biological chemistry, 2018-06, Vol.293 (23), p.9030-9040</ispartof><rights>2018 © 2018 Long et al.</rights><rights>2018 Long et al.</rights><rights>2018 Long et al. 2018 Long et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</citedby><cites>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</cites><orcidid>0000-0003-0779-1477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995523/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021925820372148$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29669811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Long, Nicholas E.</creatorcontrib><creatorcontrib>Sullivan, Brandon J.</creatorcontrib><creatorcontrib>Ding, Haiming</creatorcontrib><creatorcontrib>Doll, Stephanie</creatorcontrib><creatorcontrib>Ryan, Michael A.</creatorcontrib><creatorcontrib>Hitchcock, Charles L.</creatorcontrib><creatorcontrib>Martin, Edward W.</creatorcontrib><creatorcontrib>Kumar, Krishan</creatorcontrib><creatorcontrib>Tweedle, Michael F.</creatorcontrib><creatorcontrib>Magliery, Thomas J.</creatorcontrib><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</description><subject>Animals</subject><subject>Antibody Affinity</subject><subject>antibody engineering</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cloning, Molecular</subject><subject>colorectal cancer</subject><subject>drug development</subject><subject>Female</subject><subject>Glycoproteins - analysis</subject><subject>Glycoproteins - immunology</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>in vivo imaging</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>mucin</subject><subject>Neoplasms - diagnostic imaging</subject><subject>oligomerization</subject><subject>Positron-Emission Tomography</subject><subject>Protein Engineering</subject><subject>protein stability</subject><subject>Protein Structure and Folding</subject><subject>Single-Chain Antibodies - blood</subject><subject>Single-Chain Antibodies - genetics</subject><subject>Single-Chain Antibodies - immunology</subject><subject>Single-Chain Antibodies - pharmacokinetics</subject><subject>Tissue Distribution</subject><subject>tumor marker</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhi1ERZfCnRPyAzRb20nWMQekVQUFaSWkqpV6sxx7kkxJ7MjOVloegaeu6UIFB3wZj2f-fzz6CHnH2ZozWV3ct3Z9veW8WTMm6rJ5QVacNWVR1vzuJVnlR14oUTen5HVK9yyfSvFX5FSozUY1nK_Izx367xAp-B49QETfU_TU-AWLm-1VIcXTvQ3uQLto-gn8kmiYF5zwByTaYpiHQ0JrRjrHMENcENI5TRD3Ex3M2BUjdnCeXRwdsB-KNIPFDi0uB7rspxApTiYP79-Qk86MCd7-jmfk9vOnm8svxe7b1dfL7a6wVSWXQtlNC46pRhilpKwsc9KZjZCdrFqlKlmL2glRV23TNIq5KmeKtUYaZV3OyjPy8eg779sJnM0bRTPqOeZ_xIMOBvW_FY-D7sODrpWqa1FmA3Y0sDGkFKF71nKmf3HRmYt-4qKPXLLk_d8znwV_QOSGD8cGyJs_IESdLIK34DCCXbQL-H_3R0C6oO0</recordid><startdate>20180608</startdate><enddate>20180608</enddate><creator>Long, Nicholas E.</creator><creator>Sullivan, Brandon J.</creator><creator>Ding, Haiming</creator><creator>Doll, Stephanie</creator><creator>Ryan, Michael A.</creator><creator>Hitchcock, Charles L.</creator><creator>Martin, Edward W.</creator><creator>Kumar, Krishan</creator><creator>Tweedle, Michael F.</creator><creator>Magliery, Thomas J.</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0779-1477</orcidid></search><sort><creationdate>20180608</creationdate><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><author>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antibody Affinity</topic><topic>antibody engineering</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cloning, Molecular</topic><topic>colorectal cancer</topic><topic>drug development</topic><topic>Female</topic><topic>Glycoproteins - analysis</topic><topic>Glycoproteins - immunology</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>in vivo imaging</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>mucin</topic><topic>Neoplasms - diagnostic imaging</topic><topic>oligomerization</topic><topic>Positron-Emission Tomography</topic><topic>Protein Engineering</topic><topic>protein stability</topic><topic>Protein Structure and Folding</topic><topic>Single-Chain Antibodies - blood</topic><topic>Single-Chain Antibodies - genetics</topic><topic>Single-Chain Antibodies - immunology</topic><topic>Single-Chain Antibodies - pharmacokinetics</topic><topic>Tissue Distribution</topic><topic>tumor marker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Long, Nicholas E.</creatorcontrib><creatorcontrib>Sullivan, Brandon J.</creatorcontrib><creatorcontrib>Ding, Haiming</creatorcontrib><creatorcontrib>Doll, Stephanie</creatorcontrib><creatorcontrib>Ryan, Michael A.</creatorcontrib><creatorcontrib>Hitchcock, Charles L.</creatorcontrib><creatorcontrib>Martin, Edward W.</creatorcontrib><creatorcontrib>Kumar, Krishan</creatorcontrib><creatorcontrib>Tweedle, Michael F.</creatorcontrib><creatorcontrib>Magliery, Thomas J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Long, Nicholas E.</au><au>Sullivan, Brandon J.</au><au>Ding, Haiming</au><au>Doll, Stephanie</au><au>Ryan, Michael A.</au><au>Hitchcock, Charles L.</au><au>Martin, Edward W.</au><au>Kumar, Krishan</au><au>Tweedle, Michael F.</au><au>Magliery, Thomas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2018-06-08</date><risdate>2018</risdate><volume>293</volume><issue>23</issue><spage>9030</spage><epage>9040</epage><pages>9030-9040</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29669811</pmid><doi>10.1074/jbc.RA118.002538</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0779-1477</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9258 |
ispartof | The Journal of biological chemistry, 2018-06, Vol.293 (23), p.9030-9040 |
issn | 0021-9258 1083-351X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5995523 |
source | PubMed (Medline); ScienceDirect® |
subjects | Animals Antibody Affinity antibody engineering Antigens, Neoplasm - analysis Antigens, Neoplasm - immunology Cell Line, Tumor Cloning, Molecular colorectal cancer drug development Female Glycoproteins - analysis Glycoproteins - immunology Humans immunohistochemistry in vivo imaging Mice Mice, Inbred BALB C mucin Neoplasms - diagnostic imaging oligomerization Positron-Emission Tomography Protein Engineering protein stability Protein Structure and Folding Single-Chain Antibodies - blood Single-Chain Antibodies - genetics Single-Chain Antibodies - immunology Single-Chain Antibodies - pharmacokinetics Tissue Distribution tumor marker |
title | Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A02%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Linker%20engineering%20in%20anti-TAG-72%20antibody%20fragments%20optimizes%20biophysical%20properties,%20serum%20half-life,%20and%20high-specificity%20tumor%20imaging&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Long,%20Nicholas%20E.&rft.date=2018-06-08&rft.volume=293&rft.issue=23&rft.spage=9030&rft.epage=9040&rft.pages=9030-9040&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.RA118.002538&rft_dat=%3Cpubmed_cross%3E29669811%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29669811&rfr_iscdi=true |